J&J Medical Connect
Immunology
Immunology

Congress Materials – Gastroenterology & Hepatology Advanced Practice Providers (GhAPP 2026)

 

2026 Gastroenterology & Hepatology Advanced Practice Providers | Oct 1-3 | Chula Vista, CA

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies

Silvio Danese, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilbert van Duijnhoven, Gustavo Scapini, Shashi Adsul, David T. Rubin


This document will be available after October 1, 2026

Guselkumab for perianal fistulizing Crohn’s Disease: Week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study

Laurent Peyrin-Biroulet, Vipul Jairath, Ailsa Hart, Geert D’Haens, Axel Dignass, Silvio Danese, Julian Panés, Susan J. Connor, Walter Reinisch, David Schwartz, Tadakazu Hisamatsu, Bram Verstockt, Antonino Spinelli, Anton Stift, André D’Hoore, Maciej Nazar, Jacqueline van Denderen, Talia Gramiccia, Takehiko Sakamoto, Stephen Xu, Ivana Bravatà, and Bruce Sands on behalf of the FUZION Study Group


This document will be available after October 1, 2026

Structural Damage Progression and Clinical Response to Guselkumab in Participants With Active and Erosive Psoriatic Arthritis: Post hoc Analysis at Week 24 of the Phase 3b, Randomized, Double-blind, Placebo-controlled APEX Study

Christopher T Ritchlin, Proton Rahman, Laura C Coates, Alexa P Kollmeier, Yusang Jiang, Soumya D Chakravarty, Elizabeth Adamson, Karissa Lozenski, Arthur Kavanaugh, Philip J Mease


This document will be available after October 1, 2026

Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active Ulcerative Colitis: post-hoc analysis of QUASAR

Axel Dignass, Fumihito Hirai, Masayuki Saruta, Ayako Sasaki, Shinichi Yoshigoe, Jianmin Zhuo, Keira Herr, Tadakazu Hisamatsu


This document will be available after October 1, 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.